Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis.
PD-1
PD-L1
gastric cancer
immunotherapy
nivolumab
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Jan 2020
10 Jan 2020
Historique:
received:
24
11
2019
revised:
31
12
2019
accepted:
08
01
2020
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
6
10
2020
Statut:
epublish
Résumé
Immunotherapy has recently changed the treatment of several cancers. We performed a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall survival. Based on age (cut-off agreed at 65 years), tumour location (gastric vs. gastro-oesophageal junction), programmed death-ligand 1 (PD-L1) status, sex and Eastern Cooperative Oncology Group (ECOG) status (1 vs. 0), we scheduled a subgroup analysis for the overall survival. Three studies were included in the analysis for a total of 1456 cases (811 cases were in the experimental group and 645 cases in the control group). The pooled analysis showed improved overall survival in the experimental arm in the absence of statistical significance (hazard ratio (HR) = 0.87, 95% CI: 0.64-1.18;
Identifiants
pubmed: 31936762
pii: ijms21020448
doi: 10.3390/ijms21020448
pmc: PMC7013524
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Immunologic Factors
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cancer Med. 2018 Jun;7(6):2612-2620
pubmed: 29673110
Eur J Cancer. 2017 Nov;86:257-265
pubmed: 29055841
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Crit Rev Oncol Hematol. 2016 Apr;100:88-98
pubmed: 26895815
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
Ann Surg Oncol. 2017 Sep;24(9):2655-2668
pubmed: 28299508
Oncotarget. 2016 Jun 28;7(26):39671-39679
pubmed: 27191996
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Ann Oncol. 2018 Oct 1;29(10):2052-2060
pubmed: 30052729
Future Oncol. 2019 Jul;15(20):2423-2433
pubmed: 31237152
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Medicine (Baltimore). 2017 May;96(18):e6369
pubmed: 28471952
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Onco Targets Ther. 2018 Nov 21;11:8239-8250
pubmed: 30538493
World J Gastroenterol. 2014 Sep 7;20(33):11546-51
pubmed: 25206261
Crit Rev Oncol Hematol. 2016 Jun;102:82-8
pubmed: 27083592
J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175
pubmed: 30488824
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Expert Rev Clin Pharmacol. 2017 Mar;10(3):263-271
pubmed: 28094573
Gastric Cancer. 2019 Mar;22(2):344-354
pubmed: 30506519
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):887-92
pubmed: 27376400
J Oncol. 2019 Jul 4;2019:5692317
pubmed: 31354820
Gastric Cancer. 2017 May;20(3):407-415
pubmed: 27629881
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120